BioNTech's Late-Stage Oncology Drugs Pumitamig, Gotistobart Show Encouraging Data at ASCO
BNTX sits 17% above its 52-week low of $79.52.
Summary
BioNTech announced it will present encouraging new clinical data for its late-stage oncology assets, pumitamig and gotistobart, at the upcoming ASCO Annual Meeting. Pumitamig showed promising anti-tumor activity in first-line NSCLC, while gotistobart demonstrated durable anti-tumor activity and clinically meaningful overall survival in platinum-resistant ovarian cancer. This positive pipeline update is significant, following a period of negative news including co-founder departures, financial losses, and workforce reductions. The data could help re-establish confidence in BioNTech's core oncology strategy. Investors will watch for the full presentation details at ASCO from May 29 to June 2.
At the time of this announcement, BNTX was trading at $93.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23B. The 52-week trading range was $79.52 to $124.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.